434 Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)

• Elizabeth Evans,
• Crystal Mallow,
• Ernest Smith,
• Maurice Zauderer,
• Marya Chaney,
• Terrence Fisher,
• Amber Foster,
• John Leonard

Affiliations

Elizabeth Evans

2 Newcastle University, Newcastle upon Tyne, UK

Crystal Mallow

Aff42 grid.422076.5Vaccinex Rochester NY USA

Ernest Smith

2Vaccinex, Inc., Rochester, NY, USA

Maurice Zauderer

Aff42 grid.422076.5Vaccinex Rochester NY USA

Marya Chaney

7Merck and Co, Inc., Kenilworth, NJ, USA

Terrence Fisher

1Vaccinex, Rochester, NY, USA

Amber Foster

1Vaccinex, Rochester, NY, USA

John Leonard

1Vaccinex, Rochester, NY, USA